🇪🇺EU · EMAAuthorisedATC: N07XX05

Firdapse (previously Zenas)(amifampridine)

Lambert-Eaton Myasthenic Syndrome

Marketing Authorisation Holder: SERB SA

EMA Authorisation: 23/12/2009

INN: amifampridine

Indication

Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Firdapse (previously Zenas) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Firdapse (previously Zenas)Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.